Twist Bioscience Co. (NASDAQ:TWST) COO Sells $140,400.75 in Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,845 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $140,400.75. Following the sale, the chief operating officer now owns 269,199 shares of the company’s stock, valued at $13,284,970.65. This trade represents a 1.05 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Patrick John Finn also recently made the following trade(s):

• On Thursday, January 23rd, Patrick John Finn sold 2,422 shares of Twist Bioscience stock. The stock was sold at an average price of $50.17, for a total transaction of $121,511.74.
• On Friday, January 3rd, Patrick John Finn sold 229 shares of Twist Bioscience stock. The stock was sold at an average price of $45.59, for a total value of $10,440.11.
• On Monday, November 11th, Patrick John Finn sold 10,340 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total value of $496,320.00.

Twist Bioscience Stock Performance

TWST opened at $52.30 on Friday. Twist Bioscience Co. has a 52 week low of $27.41 and a 52 week high of $60.90. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.54. The firm has a 50-day simple moving average of $48.84 and a two-hundred day simple moving average of $46.32.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. During the same quarter last year, the business posted ($0.75) EPS. The firm’s revenue for the quarter was up 24.1% compared to the same quarter last year. Equities analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on TWST shares. TD Cowen reaffirmed a “buy” rating and set a $58.00 price objective on shares of Twist Bioscience in a research report on Tuesday, November 26th. Robert W. Baird upped their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research report on Tuesday. Scotiabank raised their price objective on shares of Twist Bioscience from $54.00 to $62.00 and gave the company a “sector outperform” rating in a research report on Tuesday. Wolfe Research assumed coverage on shares of Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Finally, Barclays decreased their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and an average price target of $53.80.

Institutional Investors Weigh In On Twist Bioscience

Several large investors have recently bought and sold shares of TWST. Massachusetts Financial Services Co. MA grew its stake in shares of Twist Bioscience by 215.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock worth $1,324,000 after buying an additional 20,035 shares in the last quarter. Barclays PLC grew its position in Twist Bioscience by 214.8% in the third quarter. Barclays PLC now owns 153,039 shares of the company’s stock worth $6,913,000 after acquiring an additional 104,420 shares in the last quarter. FMR LLC increased its stake in Twist Bioscience by 6.0% during the third quarter. FMR LLC now owns 218,561 shares of the company’s stock worth $9,875,000 after acquiring an additional 12,327 shares during the last quarter. Avanza Fonder AB purchased a new stake in Twist Bioscience during the fourth quarter valued at approximately $1,059,000. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Twist Bioscience by 128.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock worth $1,718,000 after purchasing an additional 21,357 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.